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Background: Treatment for urinary tract infections (UTIs) is usually 
empiric and is based on local antimicrobial resistance data. These 
data, however, are scarce in low-resource settings. The aim of this 
study is to determine the impact of antibiotic treatment on clinical and 
bacteriological outcomes in patients presenting with UTI symptoms to 
primary care in Harare. 
Methods: This cohort study enrolled participants presenting with UTI 
symptoms to 10 primary healthcare clinics in Harare between July 
2019 and July 2020. A questionnaire was administered and a urine 
sample was collected for culture. If the urine culture showed growth 
of ≥105 colony forming units/mL of a uropathogen, a follow up visit at 
7-21 days was conducted. 
Results: The analysis included 168 participants with a median age of 
33.6 years (IQR 25.1-51.4) and of whom 131/168 (78.0%) were female. 
Effective treatment was taken by 54/168 (32.1%) participants. The 
urine culture was negative at follow up in 41/54 (75.9%) of participants 
who took appropriate treatment and in 33/114 (28.9%, p<0.001) of 
those who did not. Symptoms had improved or resolved in 52/54 
(96.3%) of those on appropriate treatment and in 71/114 (62.3%, 
p<0.001) of those without. 
Conclusion: The findings of this study show that effective treatment 
leads to symptom resolution and bacterial clearance in people 
presenting with UTIs to primary care. Although UTIs are not life-
threatening and can resolve without treatment, they do impact on 
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quality of life, highlighting the need for optimised treatment 
recommendations.
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Introduction
Urinary tract infections (UTIs) are very common in women, 
with half of women reporting having had at least one episode 
by 32 years of age1, while they are rare in men under the age 
of 60 years2. Many women with a UTI experience moderate to 
severe symptoms impacting their daily life1. Antibiotic treat-
ment is mainly empiric and management recommendations 
are usually informed by local antimicrobial resistance (AMR) 
data collected as part of continuous surveillance3. Such data are 
not widely available in many countries in sub-Saharan Africa4. 
As a result, treatment recommendations are usually not informed 
by local or regional data, which may result in patients receiv-
ing ineffective empiric treatment. The aim of this study is to 
determine the impact of antibiotic treatment on clinical and 
bacteriological outcomes in patients presenting with UTI 
symptoms to primary care in Harare.
Methods
The data were collected as part of the Antimicrobial Resistance 
in Gram-negative bacteria from Urinary Specimens (ARGUS) 
study, which enrolled patients presenting with UTI symptoms 
to ten primary healthcare clinics in Harare between July 2019 
and July 2020. Details of the ARGUS study have been described 
elsewhere5. Briefly, adult patients (≥18 years) reporting the 
current presence of at least two symptoms suggestive of a 
UTI and who had not been recently discharged from hospital 
(within the previous 72 hours) and did not have an indwelling 
urinary catheter were eligible for inclusion into the study. Eli-
gible patients presenting to the participating clinics were 
consecutively recruited into the study. After provision of 
informed consent, a questionnaire on demographics, clinical 
history and treatment was administered and a urine sample 
collected for culture. Bacterial culture, identification and anti-
microbial susceptibility testing (AST) were performed using 
conventional microbiology techniques. AST was interpreted using 
the EUCAST standards6. ATCC reference isolates were used 
to ensure the quality of bacterial identification and AST.
If the urine culture showed growth of ≥105 colony forming 
units/mL of a uropathogen, a follow up visit at 7–21 days was 
conducted when another urine sample was collected and a 
questionnaire on symptoms, treatment and healthcare seeking 
was administered. Bacteriological cure was defined as a nega-
tive urine culture on follow up. A favourable clinical outcome 
was defined as the resolution or improvement of symptoms 
at follow up.
Treatment was prescribed by the clinic nurses according to 
routine practice and followed the national guidelines, which 
recommend amoxicillin or fluoroquinolones as first-line treat-
ment for UTIs7. Participants were considered to have received 
effective treatment if the antibiotic prescribed was shown to 
have activity against the pathogen as per the AST result and the 
participant reported having taken the antibiotic. Participants 
who had positive cultures on follow up and were symptomatic 
were prescribed effective treatment according to AST. Pregnant 
women were treated irrespective of symptoms.
This analysis excluded participants in whom the follow-up 
visit was conducted late (>21 days post enrolment), if the treat-
ment prescribed was not recorded, and if the sample could 
not be processed. Statistical analyses were performed in 
STATA v.15 (StataCorp, TX, USA). Univariable analyses were 
performed using the χ square test for categorical variables and 
Mann Whitney U test for continuous variables. Adjusted risk 
ratios were computed using Poisson regression with robust 
error variances. The analysis was adjusted for a priori confound-
ers (age and sex) and variables associated with the outcome 
in the univariable analysis at a level of significance of p <0.2. 
The exposure of interest was effective treatment. The 
outcomes were bacteriological cure and a favourable clini-
cal outcome (resolution or improvement) on follow up. Ethical 
approval for the ARGUS study was obtained from the Medical 
Research Council Zimbabwe (MRCZ/A/2406), the Institu-
tional Review Board of the Biomedical Research and Training 
Institute in Zimbabwe and the London School of Hygiene 
and Tropical Medicine Ethics committee (Ref. 16424). The 
study was conducted in accordance with the Declaration of 
Helsinki and national and institutional standards. All participants 
provided written informed consent for participation in the study.
Results
Of 1164 participants enrolled into the study, 245/1164 (21.0%) 
had a positive urine culture with ≥105 colony forming units/mL 
at baseline and in 199/245 (81.2%), a follow up visit was 
conducted (Figure 1)8. This analysis excluded 31 participants. 
The reasons for exclusion are shown in Figure 1. The analy-
sis included 168 participants with a median age of 33.6 years 
(IQR 25.1-51.4), of whom 131/168 (78.0%) were female. 
Participant characteristics are shown in Table 1. Effective treat-
ment was taken by 54/168 (32.1%) participants, while in 61/168 
(36.3%), treatment was ineffective due to resistance, in 35/168 
(20.8%) no treatment was prescribed and 18/168 (10.7%) 
did not take the prescribed treatment. Antibiotic prescrip-
tions were for amoxicillin in 59/168 (35.1%), fluoroquinolones 
in 51/168 (30.4%) and for other antibiotics in 15/168 (8.9%). 
Treatment was effective in 13/54 (24%) patients who 
took amoxicillin and in 41/46 (89%) patients who took a 
fluoroquinolone.
The urine culture was negative at follow up in 41/54 (75.9%) 
of participants who took appropriate treatment and in 33/114 
(28.9%, p<0.001) of those who did not. Symptoms had improved 
or resolved in 52/54 (96.3%) of those on appropriate treatment 
and in 71/114 (62.3%, p<0.001) of those without. Similarly, 
symptoms had improved or resolved in 67/74 (90.5%) of 
participants with a negative culture and in 56/94 (59.6%, 
p <0.001) of those with a positive culture. Participants who took 
effective treatment were more likely to have favourable clini-
cal and bacteriological outcomes, with adjusted risk ratios of 
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1.42 (1.20-1.67) and 2.63 (1.77-3.92), respectively, when 
adjusting for age, sex, HIV status and duration of symptoms 
(Table 2).
Discussion
This study shows that individuals who receive treatment 
against which the pathogen is sensitive have a significantly 
higher chance of experiencing clinical and bacteriological 
cure on follow up than those given ineffective treatment or 
not treated at all.
In line with other studies symptom resolution or improve-
ment was common even in those participants who did not 
take effective treatment. Spontaneous symptom resolution of 
uncomplicated cystitis occurs in about a third of patients9. 
However, patients without spontaneous cure often experience 
debilitating symptoms that can persist for several weeks10, affect-
ing quality of life11 and leading to economic costs due to loss 
of income, missed days at work and medical expenses1,12,13. 
Effective empiric treatment increases the speed and likelihood 
of symptom resolution and therefore is an important 
intervention at primary care level.
More than half of participants who took the prescribed 
antibiotics had infections with organisms that were resistant to 
the antibiotic prescribed. Resistance to amoxicillin was more 
frequent (76%) compared to fluoroquinolones (11%), which 
are recommended as the first-line empiric treatment of UTIs 
in outpatients in Zimbabwe7. The high prevalence of amoxicil-
lin resistance is not surprising and is in line with other reports 
from sub-Saharan Africa14. In view of the high prevalence 
of amoxicillin resistance, recommended use of the drug for 
empiric treatment of UTI needs to be reviewed. Although fluoro-
quinolones are safe and resistance is less frequent, they may not 
be the optimal choice as first-line drugs due to their potential 
for resistance development15, particularly when other low-cost 
Figure 1. Flow chart of enrolled participants.
Page 4 of 9
Wellcome Open Research 2021, 6:135 Last updated: 16 JUN 2021









Age, median (IQR) 33.6 (25.1-51.4) 30.9 (24.2-52.0) 36.6 (25.7-49.5) 0.273
Female sex 131 (78.0) 43 (79.6) 88 (77.2) 0.722
HIV positive 50 (33.8)) 9 (18.4) 41 (41.4) 0.005
Education (at least secondary) 129 (76.8) 40 (74.1) 89 (78.1) 0.567
Pregnancy 13 (10.6) 2 (5.3) 11 (12.9) 0.201
Time since the baseline visit 8 (7-11) 8 (7-10) 8 (7-11) 0.203
Duration of symptoms 6 (3-10) 5 (3-7) 7 (4-10) 0.032






































IQR: interquartile range; 20 participants did not know/disclose their HIV status; eight women did not know if 
they were pregnant.
Table 2. Association between antibiotic treatment effectiveness and clinical and 
bacteriological outcomes.
Characteristic RR (95%CI) p-value aRR (95%CI) p-value
Clinical outcome
Age (years) 0.99 (0.99-1.00) 0.890 0.99 (0.99-1.00) 0.660
Female sex 0.80 (0.68-0.95) 0.012 0.79 (0.64-0.97) 0.023
HIV infected 0.64 (0.48-0.85) 0.002 0.76 (0.59-0.99) 0.048
Duration of symptoms (days) 0.96 0.93-0.98) 0.001 0.97 (0.94-0.99) 0.014
Received effective treatment 1.55 (1.32-1.80) <0.001 1.42 (1.20-1.67) <0.001
Bacteriological outcome
Age (years) 0.99 (0.99-1.01) 0.931 1.00 (0.99-1.01) 0.632
Female sex 0.82 (0.56-1.19) 0.291 0.76 (0.51-1.14) 0.188
HIV infected 0.64 (0.40-1.03) 0.064 0.87 (0.55-1.39) 0.568
Duration of symptoms (days) 0.93 (0.89-0.98) 0.006 0.96 (0.92-1.01) 0.154
Received effective treatment 2.62 (1.89-3.63) <0.001 2.63 (1.77-3.92) <0.001
RR: risk ratio; aRR: adjusted RR; CI: confidence interval; age and duration of symptoms were analysed as 
continuous variables; duration of symptoms refers to the duration of symptoms prior to the initial clinic 
presentation (baseline visit).
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alternatives such as nitrofurantoin and fosfomycin are avail-
able. Furthermore, fluoroquinolone resistance is increasing in 
many settings16, likely driven by selective pressures exerted by 
their use and the dissemination of successful bacterial clones17. 
This highlights the need to optimise treatment recommendations 
based on setting-specific AST data.
In this study, effective treatment according to AST resulted in 
more frequent bacteriological eradication of infection and 
improved clinical outcomes. While effective treatment has been 
shown to be associated with symptom resolution and bacterio-
logical clearance in high-income settings18–20, similar data from 
sub-Saharan Africa are scarce. Some participants did not fill their 
antibiotic prescription, potentially due to costs. In addition, 
while healthcare workers may be aware that amoxicillin is not 
very effective, it may have been the only inexpensive anti-
biotic available. Thus, costs and stock outs may impact on 
antibiotic prescriptions and consequently on the effectiveness of 
treatment.
The study is limited by the relatively high rate of loss to fol-
low up explained by the economic hardships in Zimbabwe, 
preventing participants from travelling to the clinics for their 
follow up visits, and the ongoing COVID-19 pandemic, which 
led to clinic closures and a national lockdown, preventing suc-
cessful follow-up. An important strength of this study was 
the follow up of participants using culture to determine the effect 
of treatment on both clinical symptoms and bacteriological 
cure. In this study, a high proportion of participants did not 
receive effective treatment which may not be the case in other 
settings where antibiotics recommended for UTI treat-
ment reflect the local prevalence of AMR and where effective 
antibiotics are more available and affordable. However, the 
impact of effective treatment on patient outcomes would not 
be different between settings making these results generalizable.
The findings of this study show that there is a high propor-
tion of untreated UTIs, with patients often being prescribed 
antibiotics that are ineffective or not being able to afford 
treatment.
Furthermore, the long duration of symptoms prior to 
presentation suggests that some patients with UTIs may not 
present to clinics at all. Optimising treatment recommendations 
could be achieved by conducting sentinel-site surveillance for 
determining the prevalence of resistance, which would in 
turn inform empiric treatment. While UTIs have not received 
a lot of attention, partly because a high proportion resolve 
without treatment and partly because they are not life-threatening 
and the long-term morbidity is limited, they do impact on qual-
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shows, perhaps not surprisingly, that amoxicillin is not a perfect choice for empiric 
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